|
2008 Archived Releases
February 14, 2008
NUCRYST Pharmaceuticals announces year-end results
February 7, 2008
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
2007 Archived Releases
November 7, 2007
NUCRYST Pharmaceuticals announces 2007 third quarter results
October 30 2007
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
October 1, 2007
NUCRYST and Smith & Nephew Revise Agreements
August 22 2007
NUCRYST appoints new Chairman & CEO
August 8 2007
NUCRYST Pharmaceuticals announces 2007 second quarter results
August 1 2007
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Second Quarter Results
July 19 2007
NUCRYST Pharmaceuticals receives FDA clearance of antimicrobial barrier topical cream
June 27 2007
NUCRYST Pharmaceuticals appoints Katherine J. Turner, PhD to Vice President, Research and Development
June 4 2007
NUCRYST Pharmaceuticals appoints Edward Gaj Jr. Vice President, Corporate Development
May 23 2007
NUCRYST Pharmaceuticals appoints Barry M. Heck Executive Chairman
May 14 2007
NUCRYST Pharmaceuticals appoints Thomas E. Gardner to the Board of Directors
May 1 2007
NUCRYST Pharmaceuticals announces 2007 first quarter results
April 24 2007
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 first quarter results
April 5 2007
NUCRYST Pharmaceuticals Corp. Annual General Meeting of Shareholders
February 14, 2007
NUCRYST Pharmaceuticals announces year-end results
February 7 2007
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2006 Fourth Quarter Results
2006 Archived Releases
November 7, 2006
NUCRYST Pharmaceuticals announces 2006 third quarter results
November 1, 2006
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2006 Third Quarter Results
October 23, 2006
NUCRYST Pharmaceuticals Shows Effects of Nanocrystalline Silver on Ulcerative Colitis Model in Preclinical Study
September 20, 2006
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss Preliminary Results of Phase 2 Dermatology Study
September 20, 2006
NUCRYST Pharmaceuticals announces preliminary results of Phase 2 Dermatology Study
September 14, 2006
NUCRYST Pharmaceuticals’ nanocrystalline silver coating recognized for achievement in nanotechnology
August 8, 2006
NUCRYST Pharmaceuticals announces 2006 second quarter results
August 1, 2006
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2006 Second Quarter Results
June 13, 2006
NUCRYST Pharmaceuticals appoints Katherine J. Turner, Ph.D. Vice President of Research
May 30, 2006
NUCRYST Pharmaceuticals appoints Dr. David Poorvin to the Board of Directors
May 3, 2006
NUCRYST Pharmaceuticals announces 2006 first quarter results
April 27, 2006
NUCRYST Pharmaceuticals announces completion of patient enrollment in second Phase 2 clinical trial of topical cream for the treatment of atopic dermatitis
April 26, 2006
NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2006 first quarter results Wednesday May 3, 2006 8:00 a.m. EDT.
April 6, 2006
NUCRYST Pharmaceuticals Corp. will hold its Annual General Meeting of Shareholders and Investor Briefing on Friday May 5, 2006 at 10:00 a.m. EDT.
March 8, 2006
NUCRYST Pharmaceuticals granted new patent for treatment of acne. Strengthened patent portfolio now covers top three dermatology diseases
February 15, 2006
NUCRYST Pharamceuticals announces year end results
February 6, 2006
NUCRYST Pharmaceuticals announces European approval for
Acticoat™ Moisture Control
2005 Archived Releases
December 22, 2005
NUCRYST Pharmaceuticals Corp. announces pricing for Initial Public Offering
December 2, 2005
NUCRYST Pharmaceuticals Corp. files Registration Statement and
Preliminary Prospectus for Proposed Initial Public Offering
September 7, 2005
NUCRYST Pharmaceuticals appoints David C. McDowell
Vice President of Operations
August 15, 2005
NUCRYST Pharmaceuticals announces second quarter results
February 17, 2005
NUCRYST Pharmaceuticals announces year-end results
2004 Archived Releases
November 4, 2004
NUCRYST Pharmaceuticals announces third quarter results
September 7, 2004
Westaim's NUCRYST Pharmaceuticals reports Phase 2a clinical trial results of investigational drug in atopic dermatitis
May 27, 2004
NUCRYST Pharmaceuticals announces Scientific Advisory Board
May 5, 2004
NUCRYST Pharmaceuticals announces first quarter results
2003 Archived Releases
December 4, 2003
NUCRYST Pharmaceuticals begins first Phase 2 clinical trial of novel dermatology drug
November 4, 2003
NUCRYST Pharmaceuticals announces third quarter results
August 7, 2003
NUCRYST Pharmaceuticals posts record quarter
April 25, 2003
Westaim’s NUCRYST Pharmaceuticals to pursue new eczema drug
March 12, 2003
NUCRYST Pharmaceuticals announces additional European approvals
2002 Archived Releases
April 22, 2002
Westaim’s NUCRYST Pharmaceuticals appoints Paul J. Schechter to lead drug development and regulatory approval processes
2001 Archived Releases
November 1, 2001
Westaim’s NUCRYST to pursue pharmaceutical applications for its proven nanotechnology
May 9, 2001
Smith & Nephew acquires burn business and exclusive license to new wound care technology from Westaim Biomedical
February 21, 2001
Westaim Biomedical receives FDA Over-the-Counter clearance for Acticoat™ products
|
